<DOC>
	<DOCNO>NCT01453725</DOCNO>
	<brief_summary>This two-part study evaluate effect golimumab ( SCH 900259 , MK-8259 ) participant active axial spondyloarthritis ( axial SpA ) . In Part 1 , participant receive golimumab 50 mg match placebo subcutaneous injection Day 1 ( Baseline ) Weeks 4 , 8 , 12 . During Part 1 study , participant know identity injection . In Part 2 extension , participant receive golimumab 50 mg subcutaneous injection begin Week 16 every 4 week Week 48 . In Part 2 , participant tell receive active study drug . The primary hypothesis study treatment golimumab 50 mg every 4 week superior placebo measure proportion participant achieve Assessment Ankylosing Spondylitis ( ASAS ) 20 response Week 16 .</brief_summary>
	<brief_title>Effect Golimumab Participants With Active Axial Spondyloarthritis ( P07642 , MK-8259-006 )</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Active axial spondyloarthritis disease duration ≤5 year , chronic back pain ≥3 month duration Have either inadequate response 30 day optimal daily dos least one nonsteroidal antiinflammatory drug ( NSAID ) must unable receive full 30 day maximal NSAID therapy intolerance , toxicity contraindication NSAIDs Females childbearing potential must use contraception No history untreated latent active tuberculosis Fulfillment modify New York criterion ankylose spondylitis Has ever receive tumor necrosis factor ( TNF ) α target therapy biological agent Any systemic inflammatory condition spondyloarthritis Serious infection within 2 month Any known malignancy history malignancy within previous 5 year Has substance abuse ( drug alcohol ) problem within previous 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>